

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

ATTY. DOCKET NO.
064162-0032

SERIAL NO.
10/509,513

APPLICANT
Gerald Wayne BOTH, et al.

FILING DATE
October 24, 2005

GROUP
~~4003~~ **1633**

(PTO-1449)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Code ² -Number ² -Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/RMK/		VOEKS, D. ET AL, "Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludauridine in mouse models" <i>Gene Therapy</i> , 9(12), 769-788 CODEN: GETHED; ISSN: 0969-7128, 2002, XP002399217
/RMK/		LOCKETT, LINDA J. ET AL: "Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors" <i>CLINICAL CANCER RESEARCH</i> , 3(11), 2075-2080 CODEN: CCREFA; ISSN: 1078-0432, 1997, XP002399218
/RMK/		FELGNER J H ET AL: "Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations." <i>THE JOURNAL OF BIOLOGICAL CHEMISTRY</i> , 269, no. 4, pages 2550-2561, XP002399219
/RMK/		MINCHEFF M ET AL: "Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial" <i>EUROPEAN UROLOGY</i> , S. KARGER AG., BASEL, CH, vol. 38, no. 2, August 2000, pages 208-217, XP002957430

EXAMINER
/Robert Kelly/ (08/29/2007)

DATE CONSIDERED
08/29/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

DUPLICATE

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION			ATTY. DOCKET NO. 64162-032		SERIAL NO. Not yet assigned 107509513	
(PTO-1449)			APPLICANT Gerald W. BOTH, et al.			
			FILING DATE September 28, 2004		GROUP Not yet assigned-1632	
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code2 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/RMK/		US 5,908,922	05/25/1999	Whittaker et al.		
/RMK/		US 5,854,224	12/29/1998	Lockett et al		
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number - Kind Codes (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No
RMK		AU-A-27868/00 (WIPO # WO 00/52158)	09/21/2000	COMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION		Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/RMK/		VOEKS, D., et al. " Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models." Gene Therapy, Volume 9, pp. 759-768				
/RMK/		LU, Yi, "Viral Based Gene Therapy for Prostate Cancer." Current Gene Therapy, Volume 1, pp 183-200				
/RMK/		SECRIST, K., et al. " Gene Therapy of Cancer: Activation of Nucleoside Prodrugs with E. Coll Purine Nucleoside Phosphorylase." Nucleosides and Nucleotides, 18/4-5, pp. 745-757				
/RMK/		ANDERSON , Leonard, M., et al. " Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach." Cancer Gene Therapy, 7/6, pp.845-852				
EXAMINER /Robert Kelly/ (08/29/2007)			DATE CONSIDERED 08/29/2007			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.